Last reviewed · How we verify
DHA-PQ
At a glance
| Generic name | DHA-PQ |
|---|---|
| Also known as | Seasonal IPTc with Duocotexcin (Holley) |
| Sponsor | London School of Hygiene and Tropical Medicine |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Investigating the Pharmacology of Tafenoquine in Papua New Guinean Children With Uncomplicated Malaria (PHASE4)
- Mass Vaccine and Drug Administration, Bangladesh (PHASE4)
- Safety and Immunogenicity of the Malaria Vaccine, R21/MatrixM, in Healthy Thai Adults (PHASE2)
- Dihydroartemisinin-Piperaquine in the Context of Antiretroviral Therapy (PHASE4)
- Evaluation of Vector and Chemoprevention-based Interventions to Reduce Malaria Burden in Urban Daaras of Touba, Senegal (PHASE4)
- Study of Malaria Vaccine RTS,S/AS01E in Plasmodium Falciparum-infected and Uninfected Adults Pre-treated With Anti-malarial Therapy (PHASE2)
- Mass Drug Administration of Dihydroartemisinin-piperaquine + Single Low-dose Primaquine to Accelerate Toward Elimination Activities (NA)
- DHA-PQP vs Chloroquine and Primaquine for Radical Cure of Vivax Malaria in Brazil (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DHA-PQ CI brief — competitive landscape report
- DHA-PQ updates RSS · CI watch RSS
- London School of Hygiene and Tropical Medicine portfolio CI